Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule [Yahoo! Finance]
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
US:NASDAQ Investor Relations:
ir.reprosrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Royalty Pharma (NASDAQ: RPRX ) is one of the dirt cheap stocks to buy now . On February 11, Royalty Pharma reported a year of robust financial performance in 2025, marked by a 16% increase in total portfolio receipts and an 18% jump in Q4 alone. The company achieved a notable 15.8% return on invested capital and successfully met its five-year $10 billion to $12 billion capital deployment target a full year ahead of schedule. Strategically, the company completed $4.7 billion in transactions focused on attractive therapies and received a boost from several positive clinical and regulatory milestones, including the FDA approval of Myqorzo. Management highlighted the growing importance of synthetic royalties, which the company views as an increasingly popular alternative to traditional debt or equity financing for biotech firms. Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule Despite this momentum, the company is preparing for some headwin
Show less
Read more
Impact Snapshot
Event Time:
RPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RPRX alerts
High impacting Royalty Pharma plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
RPRX
News
- A Look At Royalty Pharma (RPRX) Valuation After Its Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- Biogen (BIIB) Q4 2024 Earnings Call Transcript [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Agios (AGIO) Q3 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationGlobeNewswire
- Royalty Pharma (RPRX) had its "buy" rating reaffirmed by UBS Group AG.MarketBeat
RPRX
Sec Filings
- 4/13/26 - Form 8-K
- 4/10/26 - Form ARS
- 4/10/26 - Form DEFA14A
- RPRX's page on the SEC website